肝移植中应用巴利昔单抗诱导治疗的免疫抑制方案的疗效

目的 探讨肝移植中应用巴利昔单抗诱导治疗的免疫抑制方案的疗效。方法 2007年8月至2009年7月间139例成人肝移植受者接受含巴利昔单抗诱导的免疫抑制方案（诱导组）。以2006年1月至2006年12月间接受常规免疫抑制方案的106肝移植受者为对照组。术后随访12个月，记录两组受者排斥反应、代谢并发症的发生情况，以及患者的存活情况。结果 诱导组术后1个月内急性排斥反应、糖尿病、高血压及感染的发生率分别为7.9％、33.8％、21.6％和22.3％，对照组分别为15.1％、72.6％、40.6％和43.4％，差异有统计学意义(P＜0.05)。术后12个月内，诱导组急性排斥反应、移植后新发糖尿病、高血压以及高脂血症的发生率分别为10.8％、5.0％、4.3％和7.9％，而对照组分别为19.8％、9.4％、8.5％和14.2％，差异有统计学意义(P＜0.05)。诱导组和对照组术后1年的存活率分别为92.1％和88.7％(P＞0.05)。结论 免疫抑制方案中应用巴利昔单抗诱导治疗可以早期撤除皮质激素，并可降低急性排斥反应的发生率及减少使用皮质激素引起的不良反应。

Immunosuppression regimen with Basiliximab induction in liver transplantation: efficacy and safety

Objective To investigate the effectiveness and tolerability of immunosuppressive regimen with daclizumab induction therapy. MethodsIn study group, 139 patients received immunosuppressive regimen with daclizumab induction therapy. In historical control group, 106 recipients received immunosuppressive regimen without daclizumab induction therapy. All patients were followed up at least for 1 year. The acute rejection episodes, infectious and metabolic complications at one month and one year post-transplantation were compared between two groups.Results The one-month incidence of acute rejection, new-onset diabetes mellitus, hypertension and infection was 7. 9 ％, 33. 8 ％, 21.6 ％ and 22. 3 ％, respectively in study group, as compared with 15. 1 ％, 72. 6 0％, 40. 6 ％ and 43. 4 ％, respectively in control group ( P ＜ 0. 05 ). The one-year incidence of acute rejection, new-onset diabetes mellitus, hypertension and hyperlipidemia was 10. 8 ％,5. 0 ％ ,4. 3 ％ and 7. 9 ％, respectively in study group, as compared with 19. 8 ％, 9. 4 ％, 8. 5 ％ and 14. 2 ％, respectively in control group (P＜0. 05). The one-year survival rate was comparable between two groups (P＞0. 05). Conclusion The immunosuppressive regimen with daclizumab can enable early steroid withdrawal, significantly reduce acute rejection rate and various side effects mediated by longterm steroids use.